HIV prevention: better choice for better coverage
Open Access
- 14 January 2022
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 25 (1) , e25872
Abstract
Introduction: Antiretroviral‐based pre‐exposure prophylaxis (PrEP) is today an established, effective and safe method of HIV prevention used in multiple countries worldwide by a broad range of populations at risk of HIV infection. Biomedical innovations are critical in supporting the primary prevention of HIV; however, their potential can only be maximized if end‐user challenges are recognized, described and used to develop next‐generation models.Discussion: First‐generation PrEP, a daily oral pill, is highly efficacious, discreet and affords users the ability to commence and conclude treatment rapidly. However, consistent daily adherence and persistence is challenging, especially among younger populations, due in part to side effects, the risk of stock‐outs and a lack of pill storage options. Second‐generation PrEP, longer acting agents that require less frequent dosing, could overcome such challenges. Agents that have shown efficacy in clinical trials include a monthly vaginal ring and PrEP injectables to be administered every 8 weeks, while products in development include 6 monthly injectables, oral therapy that uses monthly rather than daily pills, implants and the potential for long‐acting passive immunization.Conclusions: Second‐generation PrEP agents will have the potential to offer improved adherence and less frequent reminders once they have undergone further development and the delivery systems that will best support them have been established. In order to pursue global UNAIDS targets of reducing new HIV infections to fewer than 500,000 annually by 2025, and to ensure that all people have access to prevention options that meet their specific prevention needs, both early and next‐generation PrEP options are needed.Keywords
This publication has 40 references indexed in Scilit:
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenNew England Journal of Medicine, 2016
- Adherence to physical activity in an unsupervised setting: Explanatory variables for high attrition rates among fitness center membersJournal of Science and Medicine in Sport, 2016
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 InfectionNew England Journal of Medicine, 2015
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2015
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in BotswanaNew England Journal of Medicine, 2012
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Effectiveness of Long-Acting Reversible ContraceptionNew England Journal of Medicine, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Adherence to Exercise ProgrammesSports Medicine, 1994